SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs Neutron debut delay to 2027, following a carbon-composite dome issue, is driving the discussion. Traders are divided between concerns about repeated schedule slips and prolonged cash burn, and bullish views that the selloff is excessive given continued hardware progress and Electron launch activity.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and suspended dividend have driven a selloff, with the company citing recession-level appliance demand and some traders questioning whether broader financial and management problems are the deeper cause. The community is largely bearish on debt and bankruptcy risk, though some see the drop as an oversold bargain or potential bounce.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas better-than-expected quarterly results and ambitious 2027 outlook have renewed enthusiasm for its AI data-center and networking business after a sharp pre-earnings selloff. Traders are cheering the growth prospects, while others remain concerned about margins, cash generation and whether the strong outlook is already priced in amid volatile trading.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokias latest earnings have sparked debate: traders point to strong AI and cloud demand and a profit beat, while the sharp selloff reflects concerns about weaker free cash flow guidance, higher restructuring costs, and supply-chain pressures. The community is split between buying the post-earnings rebound as an overreaction and expecting further downside until cash generation improves.

XP, Inc. engages in the operation of technology-driven financial services platform. The firm provides customers with two principal types of offerings, financial advisory services for retail clients in Brazil, high-net-worth clients, international clients and corporate and institutional clients, and an open financial product platform providing access to over 800 investment products including equity and fixed income securities, mutual and hedge funds, structured products, life insurance, pension plans, real-estate investment funds (REITs) and others from XP, its partners and competitors. he company was founded by Guilherme Dias Fernandes Benchimol in 2001 and is headquartered in Vila Olimpia, Brazil.

XP Inc - Ordinary Shares - Class A

Lulas election victory triggered a sharp selloff across Brazilian assets, with traders attributing XPs steep decline to concerns about government spending, fiscal discipline and currency weakness. Many see the drop as an exaggerated, political-driven repricing and are buying for a possible rebound, while others warn that volatility and further downside remain risks.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

Reported advanced talks to acquire Instacart are the dominant catalyst, with traders debating whether the deal would strengthen DoorDashs grocery reach or prove costly and face antitrust hurdles. The reports have coincided with weakness in DASH, while the community notes the talks remain uncertain and could fall through.

Maplebear, Inc. engages in the design and development of an online application that offers grocery delivery and pick-up services. The firm offers Instacart which enables users to connect with personal shoppers in the area who pick up and deliver groceries from local stores. The company was founded by Apoorva Mehta, Brandon Leonardo, and Max Mullen in 2012 and is headquartered in San Francisco, CA.

Maplebear Inc.

Instacart

Reports that DoorDash is in advanced talks to acquire Instacart are driving attention, though no deal is confirmed. Traders are weighing potential takeover upside against skepticism about the valuation and the risk that talks fall through.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPals upcoming quarterly results are driving attention, with traders focused on branded-checkout growth, margins and guidance as the stock pulls back ahead of the report. Some expect continued weakness after past earnings reactions, while others hope for a beat or bank-charter update; takeover talk remains speculative.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FICOs decision to keep mortgage credit-score pricing flat, rather than raise it, and a Wells Fargo downgrade have focused attention on whether its pricing power and earnings growth are weakening. Traders are debating whether competition from VantageScore and regulatory changes pose a lasting threat, while some view the selloff as overdone.

VXX tracks an index with exposure to futures contracts on the CBOE Volatility Index with average one-month maturity. Exposure resets daily.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

VXX is drawing attention as traders debate whether a recent rebound in volatility signals renewed demand for market protection or is only a short-lived pop. Some are watching VIX technical resistance and positioning for a further volatility rise, while others expect volatility to fade and emphasize the futures ETNs decay and contango risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADPR NewswireNEW YORK, Oct. 22, 2026 NEW YORK, Oct. 22, 2026...

Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of the U.S. financial markets. Acadias management team will also host a conference call and webcast on November 4, 2026, at 4:30 p.m...

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.   New York, NY – October 21, 2026 – Brain cancer remains one of the hardest cancers to treat, and researchers are under pressure to find therapies that do more than slow the […]
The post Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market appeared first on Financial News Media.

Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?

AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADPR NewswireNEW YORK, Oct. 15, 2026NEW YORK, Oct. 15, 2026...

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.

4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADPR NewswireNEW YORK, Oct. 8, 2026NEW YORK, Oct. 8, 2026 /PRNewswire...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADPR NewswireNEW YORK, Oct. 1, 2026NEW YORK, Oct. 1, 2026 /PRNewswire...

Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041

ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia Pharmaceuticals Inc

ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets 

Equity

Extremely Bearish Sentiment

<ul class="summary-bullets"><li>According to The Fly, Needham lowered its price target to $35 from $41, and Deutsche Bank cut its target to $31 from $38, with both maintaining 'Buy' ratings.</li><li>BMO Capital lowered its target to $34 from $36, and Citizens cut its target to $33 from $36, while maintaining 'Outperform' ratings.</li><li>Acadia said the 60 mg dose narrowly missed the RADIANT primary endpoint but achieved nominal statistical significance on the key secondary endpoint, and the company is continuing the Phase 3 program.</li></ul>Acadia Pharmaceuticals (ACAD) stock was in focus Friday after multiple analysts lowered their price targets following topline results from the Phase 2 portion of the RADIANT program evaluating Remlifanserin in Alzheimer's disease psychosis.<a href="https://stocktwits.com/symbol/ACAD">ACAD</a> shares were down 5% at the time of writing on Friday.<h2 class="st-heading-2">Analysts Slash Their Price Targets On ACAD&nbsp;</h2>Needham analyst Ami Fadia lowered the firm's price target on Acadia to $35 from $41 while maintaining a 'Buy' rating, according to The Fly. The firm is updating its model following the RADIANT results, which it said failed to meet the primary endpoint for either dose, but showed meaningful results in a post-hoc analysis of a subgroup representing about 80% of patients with higher baseline severity.&nbsp;Needham is also lowering the modeled probability of success for Remlifanserin in both Alzheimer's Disease Psychosis and Lewy Body Dementia Psychosis and pushing its estimated launch timeline out by one year, Fadia said.Deutsche Bank analyst David Hoang lowered the firm's price target to $31 from $38 while maintaining a 'Buy' rating, according to TheFly. Following the RADIANT topline data, Hoang said the higher 60 mg dose narrowly missed statistical significance. The analyst added that the firm was not surprised by the stock's move and viewed the roughly $23 intraday share price as a 'valuation floor,' while saying Remlifanserin and Acadia's broader pipeline are not reflected in the stock at current levels.BMO Capital lowered its price target to $34 from $36 while maintaining an 'Outperform' rating, according to The Fly. The firm said the RADIANT miss represents a near-term headwind for the shares but that future development remains promising. BMO also said investors should not discount the potential for Remlifanserin to succeed in both Alzheimer's Disease Psychosis and Lewy Body Dementia Psychosis.Citizens lowered its price target to $33 from $36 while maintaining an 'Outperform' rating, according to The Fly. The firm said the RADIANT Phase 2 trial narrowly missed its primary endpoint at the higher dose but showed nominally significant secondary outcomes. Citizens said the efficacy signal and optimized trial design leave room for optimism around the ongoing Phase 3 program.<h2 class="st-heading-2">What Happened In The RADIANT Study?</h2>RADIANT is Acadia's global Phase 2/3 clinical program evaluating Remlifanserin for hallucinations and delusions associated with Alzheimer's disease psychosis. The Phase 2 portion evaluated 30 mg and 60 mg once-daily doses against placebo for efficacy, safety, and tolerability.The 60 mg dose narrowly missed statistical significance on the primary SAPS-H+D endpoint, with a p-value of 0.0603, but demonstrated nominal statistical significance on the key secondary Clinical Global Impression – Severity(CGI-S-ADP) endpoint, with a p-value of 0.0077. Acadia said the results showed meaningful and consistent efficacy trends across endpoints and reported a favorable safety and tolerability profile with no new safety signals.Acadia plans to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acad-stock-clocks-worst-day-in-2-years-after-alzheimer-s-psychosis-drug-misses-main-goal-citi-cuts-drug-s-success-odds-to-20/cZMJhsCRB9z">continue</a> enrolling its two ongoing Phase 3 studies evaluating Remlifanserin in Alzheimer's disease psychosis, while removing the 30 mg dose from the Phase 3 program. Separately, Remlifanserin is being evaluated in a Phase 2 study for Lewy body dementia psychosis.<h2 class="st-heading-2">Retail View On ACAD</h2>On Stocktwits, retail sentiment toward ACAD stayed ‘Bullish’ over the past 24 hours amid high message volume.ACAD shares have declined more than 23% year-to-date.Also read: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/xrp-solana-lead-crypto-majors-with-bitcoin-stuck-below-85k-etf-inlows-flip/cZMOQ5MRBOE">XRP, Solana Lead Crypto Majors With Bitcoin Stuck Below $85K, BTC ETF Inflows Turning Positive For 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena. (Photo by Sarah Reingewirtz/MediaNews Group/Los Angeles Daily News via Getty Images)

Acadia's latest trial update has put the spotlight on remlifanserin's development path, prompting analysts to reassess its near-term prospects and valuation.

ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets

Acadia's latest trial update has put the spotlight on remlifanserin's development path, prompting analysts to reassess its near-term prospects and valuation.


$HOOD (Tuesday afternoon)

$MSFT (Wednesday afternoon)

$GOOGL (Wednesday afternoon)

$AMZN (Thursday afternoon)

Which earnings release are you most excited for this week?

Drop a comment for other tickers.

Current Price	$19.74
Prev Close	$19.73
Open	$19.72
Dividend Yield	0.00%
50-Day Moving Average	$24.47
Beta	0.92
Avg. Volume	2.15M
PE Ratio	8.89

52-Week High	$30.96
52-Week Low	$18.39
Market Capitalization	$3.4B
EPS (Annual)	$2.30
Price to Book	2.60
Revenue Per Employee	$1.34M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACAD Fundamentals